Clinical trialNCT01754935CompletedPhase 2Interventional

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

SponsorVertex Pharmaceuticals IncorporatedEnrollment43Rheumatoid Arthritis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The current study is designed to evaluate the safety and efficacy, including MRI imaging, across a range of VX-509 doses in subjects with active rheumatoid arthritis (RA) who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Bradley Bloom, MD, FACR, FAAP
Vertex Pharmaceuticals Incorporated
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Denmark

Vertex Investigational Site
Hillerød, Denmark
Vertex Investigational Site
Hjørring, Denmark

Estonia

Vertex Investigational Site
Tallinn, Estonia

Lithuania

Vertex Investigational Site
Vilnius, Lithuania

Netherlands

Vertex Investigational Site
Heerlen, Netherlands
Vertex Investigational Site
Utrecht, Netherlands

South Africa

Vertex Investigational Site
Johannesburg, South Africa
Vertex Investigational Site
Pretoria, South Africa
Vertex Investigational Site
Stellenbosch, South Africa

United States

Vertex Investigational Site
Stanford, California, United States
Vertex Investigational Site
Upland, California, United States
Vertex Investigational Site
Fort Lauderdale, Florida, United States
Vertex Investigational Site
Venice, Florida, United States
Vertex Investigational Site
West Palm Beach, Florida, United States
Vertex Investigational Site
Canton, Georgia, United States
Vertex Investigational Site
Decatur, Georgia, United States
Vertex Investigational Site
Kansas City, Kansas, United States
Vertex Investigational Site
Elizabethtown, Kentucky, United States
Vertex Investigational Site
Frederick, Maryland, United States
Vertex Investigational Site
Lincoln, Nebraska, United States
Vertex Investigational Site
Rochester, New York, United States
Vertex Investigational Site
Greenboro, North Carolina, United States
Vertex Investigational Site
Duncansville, Pennsylvania, United States
Vertex Investigational Site
Charleston, South Carolina, United States
Vertex Investigational Site
Memphis, Tennessee, United States
Vertex Investigational Site
Katy, Texas, United States
Vertex Investigational Site
San Antonio, Texas, United States
Vertex Investigational Site
Webster, Texas, United States
Vertex Investigational Site
Seattle, Washington, United States
Vertex Investigational Site
Spokane, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

VX-509VX-509 matching placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2013
Primary completion: 31 Jan 2014
Completion: 28 Feb 2014
Last update posted: 19 May 2015
Registered enrollment: 43
Registry id: NCT01754935

Cross-registrations

EU-CTR / CTIS (EudraCT)2012-003439-41

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.